14:26:50 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2025-Q1
2024-11-21 Årsstämma 2025
2024-08-28 Bokslutskommuniké 2024
2024-05-25 Kvartalsrapport 2024-Q3
2024-02-22 Kvartalsrapport 2024-Q2
2023-12-14 Extra Bolagsstämma 2024
2023-11-24 Ordinarie utdelning HAMLET B 0.00 SEK
2023-11-23 Årsstämma 2024
2023-11-17 Kvartalsrapport 2024-Q1
2023-08-28 Bokslutskommuniké 2023
2023-05-26 Kvartalsrapport 2023-Q3
2023-05-17 Extra Bolagsstämma 2023
2023-02-23 Kvartalsrapport 2023-Q2
2022-11-25 Ordinarie utdelning HAMLET B 0.00 SEK
2022-11-24 Årsstämma 2023
2022-11-11 Kvartalsrapport 2023-Q1
2022-08-26 Bokslutskommuniké 2022
2022-05-20 Kvartalsrapport 2022-Q3
2022-02-25 Kvartalsrapport 2022-Q2
2021-11-26 Ordinarie utdelning HAMLET B 0.00 SEK
2021-11-25 Årsstämma 2022
2021-11-11 Kvartalsrapport 2022-Q1
2021-08-27 Bokslutskommuniké 2021
2021-06-17 Extra Bolagsstämma 2022
2021-05-21 Kvartalsrapport 2021-Q3
2021-03-02 Extra Bolagsstämma 2021
2021-02-26 Kvartalsrapport 2021-Q2
2020-11-27 Ordinarie utdelning HAMLET B 0.00 SEK
2020-11-26 Årsstämma 2021
2020-11-12 Kvartalsrapport 2021-Q1
2020-08-28 Bokslutskommuniké 2020
2020-05-22 Kvartalsrapport 2020-Q3
2020-02-28 Kvartalsrapport 2020-Q2
2019-11-22 Ordinarie utdelning HAMLET B 0.00 SEK
2019-11-21 Årsstämma 2020
2019-11-08 Kvartalsrapport 2020-Q1
2019-08-30 Bokslutskommuniké 2019
2019-05-17 Kvartalsrapport 2019-Q3
2019-02-15 Kvartalsrapport 2019-Q2
2018-11-16 Ordinarie utdelning HAMLET B 0.00 SEK
2018-11-15 Årsstämma 2019
2018-11-09 Kvartalsrapport 2019-Q1
2018-08-30 Bokslutskommuniké 2018
2018-05-18 Kvartalsrapport 2018-Q3
2018-02-16 Kvartalsrapport 2018-Q2
2017-11-10 Ordinarie utdelning HAMLET B 0.00 SEK
2017-11-09 Årsstämma 2018
2017-11-02 Kvartalsrapport 2018-Q1
2017-08-18 Bokslutskommuniké 2017
2017-05-12 Kvartalsrapport 2017-Q3
2017-02-10 Kvartalsrapport 2017-Q2
2017-01-19 Extra Bolagsstämma 2018
2016-11-18 Kvartalsrapport 2017-Q1
2016-11-11 Ordinarie utdelning HAMLET B 0.00 SEK
2016-11-10 Årsstämma 2017
2016-08-19 Bokslutskommuniké 2016
2016-05-13 Kvartalsrapport 2016-Q3
2016-02-12 Kvartalsrapport 2016-Q2
2015-11-13 Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Hamlet BioPharma är verksamt inom läkemedelsbranschen. Bolaget bedriver läkemedelsutveckling baserat på ett tumördödande protein-lipidkomplex, bildat av två naturliga och ofarliga molekyler som finns i bröstmjölk. Utvecklingen syftar till att ta fram preparat som primärt ska användas för behandling och prevention av cancersjukdomar. Studier görs idag på fall som berör blåscancer, och bolaget avser att utöka sin verksamhet till att omfatta andra cancerformer.
2023-04-14 15:20:01

In a recent evaluation of Hamlet Pharma, the European Commission concluded that Hamlet Pharma's bladder cancer project has delivered exceptional results with immediate or potential impact. The company was commended by the European Commission for the progress made during the receipt of the EU Horizon 2020 grant in the EIC Accelerator program. The European Commission concluded that the project has fully achieved its objectives and milestones for the period.

After this positive report, the Commission will now transfer to Hamlet Pharma a sum of about 300 000 EUR to be used for the bladder cancer project. This final payment to Hamlet Pharma will be made during 2023. In total, Hamlet Pharma will have received 2.2 Million EUROS as part of the EIC Accelerator program of the European Commission.

This payment from the European Commission illustrates the competitiveness of Hamlet Pharma on the international stage and the good will created by our achievements and hard work.

For more information, contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49

Catharina.svanborg@med.lu.se

Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77

martin.erixon@hamletpharma.com

Website:  www.hamletpharma.com.

About Hamlet Pharma AB

Hamlet Pharma, whose shares are listed on the Spotlight Stock Market, is a company engaged in drug development based on a tumor-killing protein-lipid complex, HAMLET, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that are primarily to be used for the treatment and prevention of cancer diseases. Alpha1H is the synthetic variant of HAMLET, which enabled the development of the substance for clinical trials. Hamlet Pharma is conducting clinical development work with Alpha1H in patients with bladder cancer, a difficult to cure and costly form of cancer. The company is also developing Alpha1H for the treatment of brain tumors and is currently conducting a Technical Evaluation of BAMLET and intends, if the evaluation turns out positive, to create conditions suitable for the continued development of BAMLET.